New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:11 EDTABT, AAgilent unit says white paper supports superiority of HER2 IQFISH pharmDx kit
Dako, an Agilent Technologies (A) company, announced positive findings in a white paper by ProPath Services, an independent anatomic pathology laboratory, comparing Dako's HER2 IQFISH pharmDx kit with Abbott's (ABT) PathVysion HER-2 DNA Probe kit. "The authors found that HER2 IQFISH pharmDxTM provided better overall quality than the PathVysion kit, defined by better signal-to-background ratio enabling more accurate determination of copy numbers. The study also concluded that the Dako kit saved 30-60 minutes of hands-on time per slide, due to less hands-on time required by lab staff, and reduced time required by the pathologist for reading and scoring," Dako said.
News For A;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
12:52 EDTABTEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
June 18, 2015
06:09 EDTABTTeva raises stake in Mylan to 4.3%, Globes reports
Subscribe for More Information
June 17, 2015
08:45 EDTABofA/Merrill life sciences analysts hold an analyst/industry conference call
Subscribe for More Information
08:32 EDTAAgilent to participate in a conference call with Janney Capital
Janney Capital hosts a conference call with Agilent Technologies' President & CEO, Michael McMullen, on June 17 at 12 pm.
June 16, 2015
14:12 EDTABTAbbott backing marginally ups chances of Mylan-Perrigo deal, says BMO Capital
Subscribe for More Information
11:06 EDTABTTeva says 'fully committed' to bid for Mylan, Bloomberg reports
After Abbott (ABT) announced earlier that it intends to vote its 14.5% stake in Mylan (MYL) in favor of Mylan's proposed acquisition of Perrigo (PRGO), a Teva (TEVA) spokesperson told Bloomberg in an email that the company remains "fully committed" to is offer to acquire Mylan, which Teva said is better than Mylan's suggested deal for Perrigo.
09:21 EDTABTMylan issues statement regarding Abbott's support for Perrigo transaction
Subscribe for More Information
09:10 EDTABTAbbott confirms support for Mylan's proposed acquisition of Perrigo
Abbott (BT) confirmed its continued support for Mylan (MYL) N.V's growth strategy by stating its intent to vote its 14.5% stake in Mylan in favor of Mylan's proposed acquisition of Perrigo (PRGO). "We chose Mylan to acquire our developed markets branded generics pharmaceuticals because its scale and breadth across critical distribution channels, broad and diverse portfolio, and commitment to patients and product quality strongly positions it for success in the years to come," said Abbott. "As both Mylan's largest shareholder and its partner through our continued manufacturing relationships, Abbott has considered the entire situation and we believe Mylan's standalone strategy and acquisition of Perrigo will further enhance its platform, is strategically compelling, value enhancing for shareholders, and offers a clear path to completion. In light of these factors, we will be voting in favor of the Perrigo transaction."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use